Abstract
Renal cell carcinoma (RCC) is a common malignancy. In 2012, in the USA, there were 65,000 new cases and 13,500 disease-specific deaths. In the same year it was the 6th most common new cancer diagnosed. During the last 50 years, despite an increase in incidence, the mortality has fallen, a possible result of earlier detection and improvements in therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 216-222 |
| Number of pages | 7 |
| Journal | Translational Andrology and Urology |
| Volume | 1 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2012 |
Open Access - Access Right Statement
Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- renal cell carcinoma
Fingerprint
Dive into the research topics of 'Biomarkers for tyrosine kinase inhibitors in renal cell cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver